Moderna (MRNA) Revenue — Quarter Ended Mar 31, 2025
Revenue declined sharply in the current quarter. The decrease was steep compared with both the prior quarter and the same quarter a year earlier.
Key takeaway
Quarter ended Mar 31, 2025 · FY2025 Q1
Revenue declined sharply in the current quarter. The decrease was steep compared with both the prior quarter and the same quarter a year earlier.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$108M
Revenue reported for this quarter.
Quarter-over-quarter
-88.8%
Change from the immediately preceding quarter.
Year-over-year
-35.3%
Change from the comparable year-ago quarter.
Trailing four quarters
$3.2B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2024 | $241M | -29.9% |
| Sep 30, 2024 | $1.9B | +1.7% |
| Dec 31, 2024 | $966M | -65.6% |
| Mar 31, 2025 | $108M | -35.3% |
Revenue performance
Reported revenue fell substantially from the immediately preceding quarter, continuing a downward trend seen in recent periods.
Quarterly comparison
Revenue was also lower than the same quarter one year ago, marking a year-over-year decline. The sequential drop was more pronounced than the annual comparison.
What to watch
The filing context does not provide specific commentary on revenue drivers for this quarter.